Eversept Partners, LP Aadi Bioscience, Inc. Transaction History

Eversept Partners, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2023	BUY	$12.03 - $14.22 $13,245 - $15,656	1,101 Added 1.09%	101,918 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $13,245 - $15,656	1,101 Added 1.09%	101,918 $1.44 Million
Q2 2022 Nov 08, 2023	SELL	$11.57 - $17.92 $578,500 - $896,000	-50,000 Reduced 33.15%	100,817 $1.24 Million
Q2 2022 Aug 15, 2022	SELL	$11.57 - $17.92 $578,500 - $896,000	-50,000 Reduced 33.15%	100,817 $1.24 Million
Q1 2022 Nov 08, 2023	BUY	$16.65 - $24.97 $814,168 - $1.22 Million	48,899 Added 47.98%	150,817 $2.56 Million
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $2.51 Million - $3.77 Million	150,817 New	150,817 $2.56 Million

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $63.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.